Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Tirzepatide, found in Mounjaro and Zepbound, mimics both GIP and GLP-1 hormones to activate insulin production. Semaglutide, ...

Meanwhile, tirzepatide – the active ingredient in Eli Lilly's weight loss shot Zepbound and diabetes drug Mounjaro –mimics two hunger-regulating hormones, GLP-1 and GIP. Novo Nordisk's weight ...

Most GLP-1 agonists are available as injections ... same active ingredient found in Mounjaro. While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing type 2 diabetes.